Secondary Logo

Institutional members access full text with Ovid®

Comparative effects of high-dose atorvastatin versus rosuvastatin on lipid parameters, oxidized low-density lipoprotein, and proprotein convertase subtilisin kexin 9 in acute coronary syndrome

Altunkeser, Bulent B.a; Tuncez, Abdullaha; Ozturk, Bahadirb; Tezcan, Huseyina; Ates, Muhammet S.a; Yilmaz, Canana; Yalcin, Muhammed U.a; Aygul, Nazifa; Demir, Kenana

doi: 10.1097/MCA.0000000000000715
Lipids
Buy

Aim Current guidelines recommend administration of high-dose statins in acute coronary syndrome (ACS). It has been reported that statins upregulate proprotein convertase subtilisin kexin 9 (PCSK9) mRNA expression and increase circulating PCSK9 levels. We aimed to compare the effects of high-dose atorvastatin and rosuvastatin on serum oxidized low-density lipoprotein (oxidized-LDL) and PCSK9 levels in statin-naive patients with ACS.

Patients and methods One hundred and six patients with ACS were enrolled in this study. The patients were assigned randomly to receive atorvastatin (80 mg/day) or rosuvastatin (40 mg/day) by using a ratio of 1 : 1 in randomization. The levels of total cholesterol (TC), triglyceride, high-density lipoprotein cholesterol, LDL-cholesterol, oxidized-LDL, and PCSK9 were compared between groups after a 4-week treatment.

Results Our study population included 53 patients in the atorvastatin group (age: 58.13±11.30 years, 11.32% female) and 53 patients in the rosuvastatin group (age: 59.08±12.44 years, 15.09% female). In both groups, lipid parameters, oxidized-LDL, and PCSK9 values changed significantly according to the baseline following treatment. High-dose atorvastatin and rosuvastatin induced similar decreases in LDL-cholesterol, oxidized-LDL, and triglyceride levels and similarly increased in high-density lipoprotein cholesterol and PCSK9 levels (P>0.05).

Conclusion We showed that atorvastatin and rosuvastatin treatment regimens have comparable effects on lipid parameters and PCSK9 levels in ACS patients.

Departments of aCardiology

bBiochemistry, Faculty of Medicine, Selcuk University, Konya, Turkey

Correspondence to Muhammed U. Yalcin, MD, Department of Cardiology, Faculty of Medicine, Selcuk University, Konya 42250, Turkey Tel: +90 332 221 0000; fax: +90 332 323 6723; e-mail: ulviyalcin@gmail.com

Received November 21, 2018

Accepted December 26, 2018

Copyright © 2019 Wolters Kluwer Health, Inc. All rights reserved.